Recommendations on screening for lung cancer

CMAJ

Volumn 188, Issue 6, 2016, Pages 425-432

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; COMPUTER ASSISTED TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FALSE POSITIVE RESULT; HEALTH CARE ACCESS; HEALTH CARE COST; HEALTH CARE DELIVERY; HEALTH CARE QUALITY; HUMAN; LUNG CANCER; MORBIDITY; PATIENT SAFETY; PRACTICE GUIDELINE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; RISK ASSESSMENT; RISK BENEFIT ANALYSIS; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE; SMOKING; SMOKING CESSATION; SYSTEMATIC REVIEW (TOPIC); THORAX RADIOGRAPHY; CANADA; EARLY CANCER DIAGNOSIS; LUNG NEOPLASMS; MASS SCREENING; STANDARDS; TRENDS;

CANADA; EARLY DETECTION OF CANCER; GUIDELINES AS TOPIC; HUMANS; LUNG NEOPLASMS; MASS SCREENING; MORBIDITY;

EID: 84962690671     PISSN: 08203946     EISSN: 14882329     Source Type: Journal    
DOI: 10.1503/cmaj.151421     Document Type: Article

References (32)

1. Canadian Cancer Society's Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2015. Toronto: Canadian Cancer Society; 2015.
2. Canadian Tobacco Use Monitoring Survey (CTUMS) 2012. Ottawa: Health Canada; 2012. Available: www.hc-sc.gc.ca/hc-ps/tobac-tabac/research-recherche/stat/ctums-esutc-2012-eng.php (accessed 2014 Jan. 22).
3. Non-small cell lung cancer survival rates by stage. Atlanta: American Cancer Society; 2015. Available: www.cancer.org/cancer/lungcancer-non-smallcell/detailedguide/non-small-cell-lung-cancer-survival-rates (accessed 2015 May 20).
4. US Preventive Services Task Force. Lung cancer screening: recommendation statement. Ann Intern Med 2004;140:738-9.
5. Palda VA, Van Spall HGC. Screening for lung cancer: updated recommendations from the Canadian Task Force on Preventive Health Care. Calgary: Canadian Task Force on Preventive Health Care; 2003. Available: canadiantaskforce.ca/files/guidelines/2003-lung-cancer-updated-recommendations-en.pdf (accessed 2016 Jan. 29).
6. Aberle DR, Adams AM, Berg CD, National Lung Screening Trial Research Team; et al. Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med 2011;365:395-409.
7. Lopes Pegna A, Picozzi G, Mascalchi M, et al. Design, recruitment and baseline results of the ITALUNG trial for lung cancer screening with low-dose CT. Lung Cancer 2009;64:34-40.
8. van Iersel CA, de Koning HJ, Draisma G, et al. Risk-based selection from the general population in a screening trial: selection criteria, recruitment and power for the Dutch-Belgian randomised lung cancer multi-slice CT screening trial (NELSON). Int J Cancer 2007;120:868-74.
9. Saghir Z, Dirksen A, Ashraf H, et al. CT screening for lung cancer brings forward early disease. The randomised Danish Lung Cancer Screening Trial: status after fve annual screening rounds with low-dose CT. Thorax 2012;67:296-301.
10. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: study design and results of the frst screening round. J Cancer Res Clin Oncol 2012;138:1475-86.
11. Canadian Task Force on Preventive Health Care procedure manual. Calgary: Canadian Task Force on Preventive Health Care; 2014. Available: canadiantaskforce.ca/files/procedural-manual-en.pdf (accessed 2016 Jan. 29).
12. Peirson L, Ali MU, Warren R, et al. Screening for lung cancer: systematic review and meta-analyses. Hamilton (ON): McMaster Evidence Review and Synthesis Centre; 2015. Available: canadian taskforce.ca/ctfphc-guidelines/2015-lung-cancer/systematic-review (accessed 2016 Feb. 25).
13. Schünemann H, Brozek J, Guyatt G, et al., editors. GRADE handbook. The GRADE Working Group; 2009. Available: gdt. guidelinedevelopment.org/central-prod/-design/client/hand book/handbook.html#h.l7zdc2r2pkyf (accessed 2016 Jan. 29).
14. Manser R, Lethaby A, Irving LB, et al. Screening for lung cancer. Cochrane Database Syst Rev 2013;(6):CD001991.
15. Becker N, Motsch E, Gross ML, et al. Randomized study on early detection of lung cancer with MSCT in Germany: results of the frst 3 years of follow-up after randomization. J Thorac Oncol 2015;10:890-6.
16. Black WC, Keeler EB, Soneji SS, et al. Cost-effectiveness of CT screening in the National Lung Screening Trial. N Engl J Med 2015;372:388.
17. Gohagan J, Marcus P, Fagerstrom R, et al. Baseline fndings of a randomized feasibility trial of lung cancer screening with spiral CT scan vs chest radiograph: the Lung Screening Study of the National Cancer Institute. Chest 2004;126:114-21.
18. Marcus PM, Prorok PC, Miller AB, et al. Conceptualizing over-diagnosis in cancer screening. J Natl Cancer Inst 2015;107:djv014.
19. Wao H, Mhaskar R, Kumar A, et al. Survival of patients with non-small cell lung cancer without treatment: a systematic review and meta-analysis. Syst Rev 2013;2:10.
20. Bashir N, Mascarenhas A, Moore J, et al. Patient preferences for Lung Cancer Screening Guideline recommendations. Toronto: La Ka Shing Institute, St. Michael's Hospital; 2015. Available: canadiantaskforce.ca/files/ctfphcpatientpreference slungcancerreport150706fnal.pdf (accessed 2016 Feb. 25).
21. Canadian Best Practices Portal: interventions. Ottawa: Public Health Agency of Canada; 2015. Available: cbpp-pcpe.phac-aspc.gc.ca/interventions/(accessed 2015 Oct. 9).
22. Lung cancer screening framework can help maximize benefts, reduce risks. Toronto: Canadian Partnership Against Cancer; 2015. Available: www.partnershipagainstcancer.ca/lung-cancer-screening-framework-can-help-maximize-benefts-reduce-risks/(accessed 2015 Oct. 9).
23. Goffn JR, Flanagan WM, Miller AB, et al. Cost-effectiveness of lung cancer screening in Canada. JAMA Oncol 2015;1:807-13.
24. Sadatsafavi M, Zafari Z, Mitton C, et al. Evaluating the Cancer Risk Management Model (CRMM)-Lung Cancer Module. Vancouver: Centre for Clinical Epidemiology and Evaluation, Vancouver Coastal Health Research Institute; 2015. Available: canadiantaskforce.ca/files/ubc-eval-crmm-lc-fnal.pdf (accessed 2016 Feb. 25).
25. Clement FM, Harris A, Li JJ, et al. Using effectiveness and cost-effectiveness to make drug coverage decisions: a comparison of Britain, Australia, and Canada. JAMA 2009;302:1437-43.
26. Roberts H, Walker-Dilks C, Sivjee K, et al. Screening high-risk populations for lung cancer. Toronto: Cancer Care Ontario; 2013.
27. Lung cancer. Atlanta (GA): American Cancer Society; 2014. Available: www.cancer.org/cancer/lungcancer/index (accessed 2014 Apr. 2).
28. Alberts WM; American College of Chest Physicians. Introduction: diagnosis and management of lung cancer: ACCP evidence-based clinical practice guidelines. Chest 2007;132(3 Suppl):20S-22S.
29. Providing guidance on lung cancer screening to patients and physicians. Washington: American Lung Association; 2012. Available: www.lung.org/assets/documents/lung-cancer/lung-cancer-screening-report.pdf (accessed 2013 Sept. 13).
30. Jaklitsch MT, Jacobson FL, Austin JH, et al. The American Association for Thoracic Surgery guidelines for lung cancer screening using low-dose computed tomography scans for lung cancer survivors and other high-risk groups. J Thorac Cardiovasc Surg 2012;144:33-8.
31. NCCN Guidelines for Patients. Lung cancer screening. Fort Washington (PA): National Comprehensive Cancer Network (NCCN); 2014. Available: www.nccn.org/patients/guidelines/lung-screening/index.html (accessed 2013 Sept. 22).
32. Clinical preventive service recommendation: lung cancer. Leawood (KS): American Academy of Family Physicians; 2013. Available: www.aafp.org/patient-care/clinical-recommendations/all/lung-cancer.html (accessed 2015 May 22).